Introduction

As the third leading cause of cancer death among both men and women and the third most common cancer in the United States, colorectal cancer is associated with substantial morbidity and mortality in the nation’s population. The rectum is the second most commonly affected site after the proximal colon, and these variations in location are also associated with differences in etiology and carcinogenesis [1]. Of the malignancies affecting the rectum, over 90% are adenocarcinomas, while squamous cell carcinomas are quite rare. Nevertheless, as more of these cases are diagnosed in the coming years, evidence-based justification of management is essential.

When compared with rectal adenocarcinoma (AC), rectal squamous cell carcinoma (SCC) occurs in approximately 0.10–0.25 per 1000 colorectal cancers [2, 3]. An autopsy study of 1464 benign and malignant rectal specimens demonstrated one rectal SCC case among 423 malignant lesions [4]. In 1933, Raiford reported the first case of SCC, and only a limited number of reports since then [5]. Previous studies have found SCC to be a distinct
entity from AC in terms of etiology, epidemiology, pathogenesis, and treatment approaches [2].

ACs are known to develop from preexisting tubular or villous adenomas via the adenomacarcinoma sequence or more rarely from dysplasia within flat mucosa, which may be associated with the development of AC in patients with hereditary nonpolyposis colorectal cancer (HNPPC) or Lynch syndrome [6]. Rectal ACs tend to affect the elderly with higher incidences in men than women and with known risk factors including obesity, sedentary lifestyle, alcohol abuse, smoking, low fiber intake, family history, and inherited conditions such as HNPPC or familial adenomatous polyposis (FAP) [7]. On the other hand, SCCs of the rectum are less understood and have multiple theories of pathogenesis. These include developmental theories such as malignant transformation of persistent ectopic embryonal nests of ectodermal cells, smoking-induced de novo mutations, previous radiation exposure, chronic rectal inflammation (e.g., ulcerative colitis), infection with human immunodeficiency virus (HIV), human papillomavirus (HPV), or enteric infections such as amebiasis or schistosomiasis due to resulting squamous metaplasia [8–15].

In addition to theories of pathogenesis, little is known regarding whether prognosis and treatment outcomes of rectal SCC differs from that of AC; it is unlikely that prospective studies, or even comparatively large retrospective cohorts, would be able to accumulate large volumes of patients to permit robust conclusions. Therefore, analyses of large population-based databases such as Surveillance, Epidemiology, and End Results (SEER) are valuable for uncommon tumors such as rectal SCC. To date, such an analysis has not been reported; therefore, the objective of this study was to compare interventions, outcomes, and prognostic factors of SCC to those of AC using the SEER database.

**Materials and Methods**

This study was approved by the Institutional Review Board. In order to analyze large volumes of patients with rectal SCC and AC, we utilized the SEER registry, which encompasses an estimated 28% of the United States population, including minority populations [16]. A total of 47,597 patients diagnosed with locoregional rectal (site code: C20.9) squamous cell carcinoma (histology code: 8070–8077) (SCC) or adenocarcinoma (histology code: 8140–8147) (AC) between 1998 and 2011 were identified from the SEER database. Metastatic cases were not chosen, as this population usually involves treatment paradigms such as palliative chemotherapy alone (i.e., no radiotherapy/surgery). Dates earlier than 1998 displayed poor/ambiguous quality of the data/treatments, and were hence excluded. Because of the importance of the following variables in our analysis, we further excluded records with missing data on grade, surgery, and radiotherapy (RT). Thus, 42,308 patients remained. Of these, 999 patients were diagnosed with SCC and 41,309 patients with AC.

Between the two histological groups, demographic, tumor, and treatment characteristics were then collated and compared. These included age (≤65 or >65), gender, race (white or non-white), median tumor size (<3.9 cm or ≥3.9 cm), grade (well-moderate or poor-undifferentiated), stage (local or regional), year of diagnosis (1998–2003 or 2004–2011), with or without surgery, and with or without RT. Cutoff values were chosen in order to balance groups’ sample sizes and avoid one-sided comparisons. Based on these candidate variables, low-, intermediate-, and high-risk groups were constructed (based on number of unfavorable risk factors) for each histologic type and outcomes compared between risk groups.

The chi-square test was used to compare the differences in proportions for the baseline patient and disease characteristics and surgery/RT receipt between the AC and SCC groups. The interval-to-event distributions were estimated using the Kaplan–Meier method and compared using the log rank test. A 1:1 case–control match on the propensity score with Greedy algorithms was used to balance groups by creating a cohort of patients with AC (control) that was comparable on all observed covariates (prognostic factors) to a group of patients with SCC (case) [17]. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression with variants of living status as the time metric. Stepwise elimination was used to select variables for multivariable adjusted models characterizing the association of histology (SCC vs. AC) with overall survival. A P < 0.05 was considered significant. All statistical calculations were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

**Results**

**Patient characteristics**

As summarized in Table 1, the median age was 61 for patients with SCC and 66 for patients with AC; there were similar racial incidence. In contrast to AC, which affected females in 40% of cases, SCC affected females in 69%. Sixty-four percent of SCC cases presented with localized stage, as compared with 47% in AC. However, 46% of SCCs were histologic grade 3/4 at diagnosis, as compared to 15% of AC cases as such.

Forty percent of SCC patients underwent surgery, and 75% received RT. In AC, 89% underwent surgery, and
59% received RT. Although the majority of both SCC and AC were diagnosed between 2004 and 2011, the percent was higher for SCC (67%) than for AC (61%).

**Survival analysis**

As shown in Figure 1A, surgery improved overall survival (OS) in AC (median survival (MS) 106 months with surgery vs. 22 months without, \( P < 0.0001 \)), but seemed to have no effect on SCC (MS 96 months with surgery vs. 108 months without, \( P = 0.796 \)). Figure 1B demonstrates the effect of RT on AC (MS 110 months with RT vs. 76 months without, \( P < 0.0001 \)), but revealed a relatively greater magnitude of improvement in OS in the SCC group (MS 135 months with RT vs. 51 months without, \( P < 0.0001 \)).

Other notable prognostic factors were associated with survival, as quantitated in Table 2. Stage of presentation had a statistically significant impact on OS in both groups (\( P < 0.0001 \)). Though there were statistically more high-grade tumors in the SCC group, grade influenced OS in AC (\( P < 0.0001 \)), but not SCC (\( P = 0.900 \)). Younger age and female gender were associated with improved outcomes as well; age in both SCC/AC (\( P < 0.0001 \)), and gender in SCC (\( P < 0.0001 \)) but not AC (\( P = 0.332 \)). Lastly, tumor size was a relevant factor in both groups (\( P < 0.0001 \)), especially SCC.

Using the aforementioned prognostic factors, low-, intermediate-, and high-risk groups were then constructed for each histologic type. SCC risk factors included stage (regional disease), gender (male), and age (>65 years), whereas those for AC included stage (regional disease), grade (high), and age (>65 years). The high-risk group for each histologic subtype required all three risk factors, the intermediate-risk group 1–2 risk factors, and the low-risk required the absence of all three.

Figure 2 and Table 3 compare SCC and AC in their respective risk groups. In SCC, surgery did not seem to be associated with higher OS among each risk group (\( P > 0.05 \) for all groups), whereas there was a strong
association in AC cases \( (P < 0.0001 \text{ for all groups}) \). When assessing the effect of RT, however, both SCC and AC displayed higher OS when RT was performed in both intermediate- \( (P < 0.0001 \text{ for both SCC and AC}) \) and high-risk \( (P = 0.007 \text{ for SCC}, P < 0.0001 \text{ for AC}) \) subgroups. An alternative presentation of the data based on risk groups in all patients, those that underwent surgery, and those that did not undergo surgery are presented in Figures S1–S3, respectively, corresponding to Table S1.

**Prognostic factors**

Prognostic factors for 5-year OS included histology (AC vs. SCC), surgery (with vs. without), RT (with vs. without), stage (regional vs. local), age (>65 vs. ≤65), gender (male vs. female), and race (white vs. non-white). Favorable prognostic factors for all-comers included SCC histology, having undergone surgery, receipt of RT, local stage, younger age, female gender, and white race.
Rectal Squamous Cell and Adenocarcinoma

M. S. Chiu et al.

After adjusting for relevant prognostic factors in all patients, patients with AC were less likely to survive ≥5 years, relative to their SCC counterparts (Fig. S4; odds ratio [OR]: 0.838; 95% CI: 0.720–0.974). This was also true in patients who had not undergone surgery (Fig. S5; OR: 0.533; 95% CI: 0.422–0.674). However, for patients who had undergone surgery, patients with AC were more likely to survive ≥5 years, relative to their SCC counterparts (Fig. S6; OR: 1.516; 95% CI: 1.227–1.873).

Propensity score matching analysis

Propensity score matching was used to select AC and SCC cases with equal distributions of all observed covariates, in effort to examine the associations of survival with histology alone. Table S2 shows that patient, tumor, and treatment characteristics of the 907 patients in each group of the matched population were statistically insignificant in all analyzed variables except year interval of diagnosis.

In the matched data, AC was significantly associated with increased risk of overall death as compared to SCC in both univariate (HR = 1.156; 95% CI: 1.009–1.323) and multivariate (HR = 1.228; 95% CI: 1.021–1.475) Cox proportional hazard regression models (Table 4).

Discussion

Diagnoses of rectal SCC are rising over time, despite high-volume evidence regarding treatment options and modalities. Despite the rarity of rectal SCC, this is the first known study to study a large population-based sample of patients (n = 999) with rectal SCC. To the best of our knowledge, the second-largest report evaluated just 107 patients, with details unavailable owing to the non-English language nature of the publication [18]. We found that the majority of patients with SCC were treated with RT, whereas the majority of patients with AC were treated with surgery; the patients with SCC showed a significantly superior OS. In

Figure 2. (A). Comparison of overall survival in rectal squamous cell carcinoma patients, as stratified for risk status and receipt of surgery. (B). Comparison of overall survival in rectal adenocarcinoma patients, as stratified for risk status and receipt of surgery. (C). Comparison of overall survival in rectal squamous cell carcinoma patients, as stratified for risk status and receipt of RT. RT, radiotherapy. (D). Comparison of overall survival in rectal adenocarcinoma patients, as stratified for risk status and receipt of RT. RT, radiotherapy.
addition to SCC histology, other factors associated with higher survival in the entire cohort (AC + SCC) included receipt of RT, undergoing surgery, local stage, younger age, female gender, and white race. When stratified by histology, receipt of surgery and race were no longer prognostic factors for survival in patients with SCC histology. Propensity score matching also illustrated that histology (SCC greater than AC) was a significant associate of survival after controlling for nearly all remaining variables.

Although treatment for AC most commonly involves surgery alone for early localized disease and chemoradiation therapy followed by surgical resection (if possible) followed by adjuvant chemotherapy for T3/T4, node-positive, and technically/medically unresectable disease [19], guidelines for rectal SCC are less clear owing to a lack of high-volume data. Surgical resection is a consideration [20], but increasing numbers of recent studies are also finding merit to treat with definitive CRT using

Table 2. Median overall survivals of rectal adenocarcinomas versus squamous cell carcinomas, stratified for several variables, corresponding to Figure 1 and Figures S1–S5.

|                          | Squamous cell carcinoma | Adenocarcinoma          |
|--------------------------|-------------------------|-------------------------|
|                          | Median OS (mo) (95% CI) | Log-rank P value       |
|                          |                         |                         |
| Surgery                  | 0.796                   | <0.0001                 |
| Yes                      | 96 (69–123)             | 106 (104–109)           |
| No                       | 108 (83–139)            | 22 (21–24)              |
| RT                       | <0.0001                 | <0.0001                 |
| Yes                      | 135 (102–147)           | 110 (106–113)           |
| No                       | 51 (22–70)              | 76 (74–79)              |
| Stage                    | <0.0001                 | <0.0001                 |
| Local                    | 119 (105–139)           | 115 (112–119)           |
| Regional                 | 40 (30–78)              | 76 (74–79)              |
| Grade                    | 0.900                   | <0.0001                 |
| Low                      | 107 (93–136)            | 99 (97–102)             |
| High                     | 95 (75–136)             | 68 (64–73)              |
| Age                      | <0.0001                 | <0.0001                 |
| ≤65                      | 136 (119–167)           | Not reached             |
| >65                      | 39 (29–59)              | 58 (57–60)              |
| Gender                   | <0.0001                 | 0.332                   |
| Male                     | 123 (105–149)           | 98 (94–101)             |
| Female                   | 57 (36–93)              | 93 (90–95)              |
| Tumor size               | <0.0001                 | <0.0001                 |
| ≤3.9 cm                  | 115 (111–119)           | 129 (126–132)           |
| >3.9 cm                  | 85 (81–88)              | 110 (102–118)           |

OS, overall survival; RT, radiotherapy; CI, confidence intervals.

Table 3. Median overall survivals of rectal adenocarcinomas versus squamous cell carcinomas, stratified for treatment intervention and risk groups, corresponding to Figure 2.

|          | Low Risk                                | Intermediate Risk                                      | High Risk                                           |
|----------|-----------------------------------------|-------------------------------------------------------|
|          | MS (mo) (95% CI) Log-rank P value        | MS (mo) (95% CI) Log-rank P value                      | MS (mo) (95% CI) Log-rank P value                    |
| SCC      | SCC                                    | SCC                                                   | SCC                                                  |
| Surgery  | Not reached                             | 0.853                                                 | 0.459                                                |
| No surgery | 158 (136–165)                          | 71 (41–97)                                            | 18 (4–72)                                           |
| RT       | Not reached                             | 0.219                                                 | <0.0001                                              |
| No RT    | Not reached                             | 23 (15–43)                                            | 4.5 (1–18)                                          |
| AC       | AC                                     | AC                                                    | AC                                                   |
| Surgery  | Not reached                             | <0.0001                                               | 0.007                                                |
| No surgery | 64 (50–78)                             | 90 (88–93)                                            | 37 (33–39)                                          |
| RT       | Not reached                             | 0.036                                                 | <0.0001                                              |
| No RT    | Not reached                             | 97 (94–100)                                           | 39 (36–43)                                          |

MS, median survival; CI, confidence interval; SCC, squamous cell carcinoma; AC, adenocarcinoma; RT, radiotherapy.
the anal SCC paradigm [21, 22]. Along with the data herein, several series have shown high clinical response as well as clinical complete response rates from 63% to 100% along with 5-year overall survival, disease-free survival, and disease-specific survival rates of 81%, 72%, and 88%, respectively [9, 23–28].

There are several limitations of our analysis. In addition to the inherently retrospective nature of SEER studies as well as individualized follow-up, it must be prominently mentioned that causation can neither be stated nor implied with these data, especially regarding treatment interventions and survival. Additionally, lack of chemotherapy records makes these data somewhat incomplete. It would be helpful to know the response of rectal SCCs to chemotherapy in efforts to escalate or deescalate therapy accordingly. Additionally, there could have been a degree of selection bias in those patients that did not receive surgery, potentially owing to additional comorbidities impacting outcomes. A noted selection bias was the inclusion of nonmetastatic cases, but as previously noted, most metastatic cases receive RT only for palliation; these patients were hence beyond the scope of our specific clinical question. Removal of cases with missing data could also introduce bias, but this proportion was low; moreover, it was a necessity to have basic data for subgroup/prognostic analyses. Furthermore, it cannot be understated that misdiagnosis is a limitation of any population-based study, even regardless of the specific database used. It can never be known whether every patient in this study had true rectal SCC, because many rectal SCC cases are the result of misdiagnosis of anal squamous cell carcinomas with proximal extension into the rectum [8]. Whether there are true prognostic differences between “true” SCCs of the rectum and anus remains to be addressed, but other groups have been able to find outcome differences between anal SCCs and anal ACs [29].

**Table 4.** Cox proportional hazards models built on propensity score-matched data.

| Variable          | Univariate model | Multivariate model | Selected=stepwise |
|-------------------|------------------|--------------------|-------------------|
| **Histology**     |                  |                    |                   |
| SCC Reference     | 1.156 (1.009–1.323) | 0.0363             |                   |
| AC                | 1.270 (1.057–1.527) | 0.011              |                   |
| **Age**           |                  |                    |                   |
| 19–65 Reference   | 2.243 (1.959–2.568) | <0.0001            |                   |
| 66–100 Reference  | 2.402 (1.998–2.887) | <0.0001            |                   |
| **Gender**        |                  |                    |                   |
| Male Reference    | 1.256 (1.093–1.443) | 0.0013             |                   |
| Female Reference  | 1.363 (1.132–1.640) | 0.001              |                   |
| **Tumor size**    |                  |                    |                   |
| >3.9 cm Reference | 1.739 (1.445–2.094) | <0.0001            |                   |
| ≤3.9 cm Reference | Not included due to missing data (40%) |                   |                   |
| **Race**          |                  |                    |                   |
| White Reference   | 0.994 (0.827–1.194) | 0.949              |                   |
| Non-white Reference | Reference        |                    |                   |
| **Stage**         |                  |                    |                   |
| Localized Reference | 1.460 (1.272–1.676) | <0.0001            |                   |
| **Grade**         |                  |                    |                   |
| 1 and 2 Reference | 1.544 (1.342–1.777) | <0.0001            |                   |
| 3 and 4 Reference | Not included due to missing data (40%) |                   |                   |
| **Surgery**       |                  |                    |                   |
| Yes Reference     | 0.609 (0.530–0.700) | <0.0001            |                   |
| No Reference      | 0.603 (0.498–0.731) | <0.0001            |                   |
| **Radiation therapy** |                |                    |                   |
| Yes Reference     | 0.653 (0.565–0.755) | <0.0001            |                   |
| No Reference      | 0.533 (0.462–0.616) | <0.0001            |                   |
| **Year of diagnosis** |            |                    |                   |
| 1998–2003 Reference | 1.122 (0.972–1.296) | 0.065              |                   |

Only statistically significant variables are shown in the table. HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; AC, adenocarcinoma.
There remains much need for further elucidation. It would be important to know the clinical and pathologic response rates for rectal SCC with CRT or RT alone, as well as patterns of failure, which can only be possible using more detailed clinical data than what is available in SEER. Furthermore, it remains to be seen whether subsets of rectal SCC (low-risk subgroup) with the best prognosis could be afforded deescalated therapy (and vice-versa with high-risk groups), with appropriate surgical salvage in those specific circumstances. Lastly, a study has also found the presence of the SCC antigen, which was present in 50% of studied patients, but decreased with treatment and as correlated with complete response [23]. The value of such a marker is unknown, is far from validated, and also must be further investigated.

Conclusions
In the largest analysis of rectal SCC to date, nonsurgical, RT-based treatment is recommended. Recognizing that prospective data for this rare tumor will be difficult to accrue, future population-based analyses should continue to build on the implications of results in this SEER analysis.

Acknowledgments
None. There was no funding support for this study. This has been presented in part at the American Society of Radiation Oncology 2015 Annual Meeting.

Conflicts of Interest
The authors all declare that conflicts of interest do not exist.

References
1. Siegel, R., C. DeSantis, and A. Jemal. 2014. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 64:104–117.
2. Dyson, T., and P. V. Draganov. 2009. Squamous cell cancer of the rectum. World J. Gastroenterol. 15:4380–4386.
3. Anagnostopoulos, G., G. H. Sakorafas, P. Kostopoulos, K. Grigoriadis, G. Pavlakis, G. Margantinis, et al. 2005. Squamous cell carcinoma of the rectum: a case report and review of the literature. Eur. J. Cancer Care (Engl) 14:70–74.
4. Terada, T. 2013. Histopathologic study of the rectum in 1,464 consecutive rectal specimens in a single Japanese hospital: II. malignant lesions. Int. J. Clin. Exp. Pathol. 6:385.
5. Raiford, T. 1933. Epitheliomata of the lower rectum and anus. Surg. Gynecol. Obstet. 57:21–35.
6. Buetow, P. C., J. L. Buck, N. J. Carr, and L. Pantongrag-Brown. 1995. From the archives of the AFIP. colorectal adenocarcinoma: radiologic-pathologic correlation. Radiographics 15:127–146; quiz 148-9.
7. Wei, E. K., E. Giovannucci, K. Wu, B. Rosner, C. S. Fuchs, W. C. Willett, et al. 2004. Comparison of risk factors for colon and rectal cancer. Int. J. Cancer 108:433–442.
8. Yeh, J., J. Hastings, A. Rao, and M. Abbas. 2012. Squamous cell carcinoma of the rectum: a single institution experience. Tech. Coloproctol. 16:349–354.
9. Nahas, C. S., J. Shia, R. Joseph, D. Schrag, B. D. Minsky, M. R. Weiser, et al. 2007. Squamous-cell carcinoma of the rectum: a rare but curable tumor. Dis. Colon Rectum 50:1393–1400.
10. Williams, G. T., A. Blackshaw, and B. Morson. 1979. Squamous carcinoma of the colorectum and its genesis. J. Pathol. 129:139–147.
11. Fu, K., Y. Tsujinaka, Y. Hamahata, K. Matsuo, and O. Tsutsumi. 2008. Squamous metaplasia of the rectum associated with ulcerative colitis diagnosed using narrow-band imaging. Endoscopy 40(Suppl 2):E45–E46.
12. Yurdakul, G., T. M. de Reijke, L. E. Blank, and E. A. Rauws. 2003. Rectal squamous cell carcinoma 11 years after brachytherapy for carcinoma of the prostate. J. Urol. 169:280.
13. Leung, K. K., J. Heitzman, and A. Madan. 2009. Squamous cell carcinoma of the rectum 21 years after radiotherapy for cervical carcinoma. Saudi J. Gastroenterol. 15:196–198.
14. Frizelle, F. A., K. S. Hobday, K. P. Batts, and H. Nelson. 2001. Adenosquamous and squamous carcinoma of the colon and upper rectum: a clinical and histopathologic study. Dis. Colon Rectum 44:341–346.
15. Audeau, A., H. W. Han, M. J. Johnston, M. W. Whitehead, and F. A. Frizelle. 2002. Does human papilloma virus have a role in squamous cell carcinoma of the colon and upper rectum? Eur. J. Surg. Oncol. 28:657–660.
16. Surveillance, Epidemiology, and End Results Program. Overview of the SEER program. [Internet] [cited 2015 September 17]. Available at: http://seer.cancer.gov/about/overview.html (accessed 7 January 2015).
17. Performing a 1: N case-control match on propensity score. 2004. Proceedings of the 29th annual SAS users group international conference. Proceedings of the 29th annual SAS users group international conference, Cary, NC.
18. Mel’nikov, R. A., L. G. Goshchitskii, and V. K. Kovalev. 1984. Clinical manifestations of squamous cell carcinoma of the rectum. Vopr. Onkol. 30:76–83.
19. National Comprehensive Cancer Network. Rectal Cancer (Version 3.2015) [Internet]. Available at: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
20. Kassir, R., S. Baccot, N. Bouarioua, C. A. Petcu, J. Dubois, A. Boueil-Bourlier, et al. 2014. Squamous cell carcinoma of middle rectum: literature review. Int. J. Surg. Case Rep. 5:86–90.
21. Glynn-Jones, R., P. J. Nilsson, C. Aschele, V. Goh, D. Peiffert, A. Cervantes, et al. 2014. Anal cancer: eSMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother. Oncol. 111:330–339.
22. National Comprehensive Cancer Network. Anal Carcinoma (Version 2.2015) [Internet]. Available at: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. (accessed 7 January 2015)
23. Rasheed, S., T. Yap, A. Zia, P. McDonald, and R. Glynn-Jones. 2009. Chemoradiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum–report of six patients and literature review. Colorectal Dis. 11:191–197.
24. Clark, J., S. Cleator, R. Goldin, C. Lowdell, A. Darzi, and P. Ziprin. 2008. Treatment of primary rectal squamous cell carcinoma by primary chemoradiotherapy: should surgery still be considered a standard of care? Eur. J. Cancer 44:2340–2343.
25. Sturgeon, J. D., C. H. Crane, S. Krishnan, B. D. Minsky, J. M. Skibber, M. A. Rodriguez-Bigas, et al. 2014. Definitive chemoradiation for squamous cell carcinoma of the rectum. Am. J. Clin. Oncol. [Epub ahead of print].
26. Musio, D., F. De Felice, S. Manfrida, M. Balducci, E. Meldolesi, G. L. Gravina, et al. 2015. Squamous cell carcinoma of the rectum: the treatment paradigm. Eur. J. Surg. Oncol. 41:1054–1058.
27. Peron, J., O. Bylicki, C. Laude, I. Martel-Lafay, C. Carrie, and S. Racadot. 2015. Nonoperative management of squamous-cell carcinoma of the rectum. Dis. Colon Rectum 58:60–64.
28. Wang, M. L., A. Heriot, T. Leong, and S. Y. Ngan. 2011. Chemoradiotherapy in the management of primary squamous-cell carcinoma of the rectum. Colorectal Dis. 13:296–301.
29. Franklin, R. A., S. Giri, P. Valasareddy, L. T. Lands, and M. G. Martin. 2016. Comparative survival of patients with anal adenocarcinoma, squamous cell carcinoma of the anus, and rectal adenocarcinoma. Clin. Colorectal Cancer 15:47–53.

**Supporting Information**

Additional supporting information may be found in the online version of this article:

**Figure S1.** Comparison of overall survival between all patients with rectal AC and SCC using risk stratification. SCC, squamous cell carcinoma; AC, adenocarcinoma.

**Figure S2.** Comparison of overall survival between patients with rectal AC and SCC who underwent surgery, using risk stratification. SCC, squamous cell carcinoma; AC, adenocarcinoma.

**Figure S3.** Comparison of overall survival between patients with rectal AC and SCC who did not undergo surgery, using risk stratification. SCC, squamous cell carcinoma; AC, adenocarcinoma.

**Figure S4.** Analysis of factors influencing overall survival rates in all patients. Numerical odds ratios for each variable are as follows: histology (<1, favor SCC; >1, favor AC), surgery (<1, favor no surgery; >1, favor surgery), RT (<1, favor no RT; >1, favor RT), stage (<1, favor local; >1, favor regional), age (<1, favor ≤ 65 years; >1, favor > 65 years), gender (<1, favor female; >1, favor male), race (<1, favor non-white; >1, favor white), grade (<, favor low-grade; >1, favor high-grade). SCC, squamous cell carcinoma; AC, adenocarcinoma; RT, radiotherapy; Reg, regional; Loc, local; M, male; F, female; W, while; NW, non-white; H, high-grade; L, low-grade.

**Figure S5.** Analysis of factors influencing overall survival rates in patients without surgery. Numerical odds ratios for each variable are as follows: histology (<1, favor SCC; >1, favor AC), RT (<1, favor no RT; >1, favor RT), stage (<1, favor local; >1, favor regional), age (<1, favor ≤ 65 years; >1, favor > 65 years), gender (<1, favor female; >1, favor male), race (<1, favor non-white; >1, favor white), grade (<, favor low-grade; >1, favor high-grade). SCC, squamous cell carcinoma; AC, adenocarcinoma; RT, radiotherapy; Reg, regional; Loc, local; M, male; F, female; W, while; NW, non-white; H, high-grade; L, low-grade.

**Figure S6.** Analysis of factors influencing overall survival rates in patients with surgery. Numerical odds ratios for each variable are as follows: histology (<1, favor SCC; >1, favor AC), RT (<1, favor no RT; >1, favor RT), stage (<1, favor local; >1, favor regional), age (<1, favor ≤ 65 years; >1, favor > 65 years), gender (<1, female; >1, favor male), race (<1, favor non-white; >1, favor white), grade (<, favor low-grade; >1, favor high-grade). SCC, squamous cell carcinoma; AC, adenocarcinoma; RT, radiotherapy; Reg, regional; Loc, local; M, male; F, female; W, while; NW, non-white; H, high-grade; L, low-grade.

**Table S1.** Median overall survivals of rectal adenocarcinomas versus squamous cell carcinomas stratified for treatment intervention and risk groups, corresponding to Figures S6–S8. MS, median survival; CI, confidence interval; SCC, squamous cell carcinoma; AC, adenocarcinoma; RT, radiotherapy.

**Table S2.** Propensity score analysis demonstrating characteristics of the 1:1 matched population. SCC, squamous cell carcinoma; AC, adenocarcinoma.